These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16552081)

  • 1. Human neutrophil calprotectin reduces the susceptibility of Borrelia burgdorferi to penicillin.
    Montgomery RR; Schreck K; Wang X; Malawista SE
    Infect Immun; 2006 Apr; 74(4):2468-72. PubMed ID: 16552081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calprotectin, an abundant cytosolic protein from human polymorphonuclear leukocytes, inhibits the growth of Borrelia burgdorferi.
    Lusitani D; Malawista SE; Montgomery RR
    Infect Immun; 2003 Aug; 71(8):4711-6. PubMed ID: 12874352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial action of calprotectin that does not involve metal withholding.
    Besold AN; Culbertson EM; Nam L; Hobbs RP; Boyko A; Maxwell CN; Chazin WJ; Marques AR; Culotta VC
    Metallomics; 2018 Dec; 10(12):1728-1742. PubMed ID: 30206620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline.
    Feng J; Auwaerter PG; Zhang Y
    PLoS One; 2015; 10(3):e0117207. PubMed ID: 25806811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persister Development by Borrelia burgdorferi Populations In Vitro.
    Caskey JR; Embers ME
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6288-95. PubMed ID: 26248368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi.
    Wu X; Sharma B; Niles S; O'Connor K; Schilling R; Matluck N; D'Onofrio A; Hu LT; Lewis K
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126963
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.
    Pothineni VR; Wagh D; Babar MM; Inayathullah M; Solow-Cordero D; Kim KM; Samineni AV; Parekh MB; Tayebi L; Rajadas J
    Drug Des Devel Ther; 2016; 10():1307-22. PubMed ID: 27103785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Borrelia burgdorferi Group: in-vitro antibiotic sensitivity].
    Henneberg JP; Neubert U
    Orv Hetil; 2002 May; 143(21):1195-8. PubMed ID: 12073540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between antibiotics and human neutrophils in the killing of staphylococci.
    Root RK; Isturiz R; Molavi A; Metcalf JA; Malech HL
    J Clin Invest; 1981 Jan; 67(1):247-59. PubMed ID: 7451652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recruitment of macrophages and polymorphonuclear leukocytes in Lyme carditis.
    Montgomery RR; Booth CJ; Wang X; Blaho VA; Malawista SE; Brown CR
    Infect Immun; 2007 Feb; 75(2):613-20. PubMed ID: 17101663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline.
    Brorson Ø; Brorson SH; Scythes J; MacAllister J; Wier A; Margulis L
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18656-61. PubMed ID: 19843691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to tinidazole.
    Brorson O; Brorson SH
    Int Microbiol; 2004 Jun; 7(2):139-42. PubMed ID: 15248163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of tigecycline against multiple strains of Borrelia burgdorferi.
    Yang X; Nguyen A; Qiu D; Luft BJ
    J Antimicrob Chemother; 2009 Apr; 63(4):709-12. PubMed ID: 19182236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the interaction of Borrelia burgdorferi with decorin significantly reduces the 50 percent infectious dose and severely impairs dissemination.
    Xu Q; Seemanaplli SV; McShan K; Liang FT
    Infect Immun; 2007 Sep; 75(9):4272-81. PubMed ID: 17562764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Borrelia burgdorferi NapA-driven Th17 cell inflammation in lyme arthritis.
    Codolo G; Amedei A; Steere AC; Papinutto E; Cappon A; Polenghi A; Benagiano M; Paccani SR; Sambri V; Del Prete G; Baldari CT; Zanotti G; Montecucco C; D'Elios MM; de Bernard M
    Arthritis Rheum; 2008 Nov; 58(11):3609-17. PubMed ID: 18975343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyruvate protects pathogenic spirochetes from H2O2 killing.
    Troxell B; Zhang JJ; Bourret TJ; Zeng MY; Blum J; Gherardini F; Hassan HM; Yang XF
    PLoS One; 2014; 9(1):e84625. PubMed ID: 24392147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phagocytosis of Borrelia recurrentis by blood polymorphonuclear leukocytes is enhanced by antibiotic treatment.
    Butler T; Aikawa M; Habte-Michael A; Wallace C
    Infect Immun; 1980 Jun; 28(3):1009-13. PubMed ID: 7399684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment.
    Bockenstedt LK; Mao J; Hodzic E; Barthold SW; Fish D
    J Infect Dis; 2002 Nov; 186(10):1430-7. PubMed ID: 12404158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.
    Johnson RC; Kodner C; Russell M
    Antimicrob Agents Chemother; 1987 Feb; 31(2):164-7. PubMed ID: 3566246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to Borrelia burgdorferi in patients with antibiotic-refractory, antibiotic-responsive, or non-antibiotic-treated Lyme arthritis.
    Kannian P; McHugh G; Johnson BJ; Bacon RM; Glickstein LJ; Steere AC
    Arthritis Rheum; 2007 Dec; 56(12):4216-25. PubMed ID: 18050219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.